SIWA THERAPEUTICS

They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the removal of SCs. SCs are causally implicated in age-related dysfunction and in degenerative disease. These cells act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them has been shown to improve healthspan and lifespan.